Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2008
02/14/2008WO2008002569A3 Human protein tyrosine phosphatase inhibitors and methods of use
02/14/2008WO2008002245A3 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
02/14/2008WO2008002244A3 Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
02/14/2008WO2008000950A3 Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
02/14/2008WO2007149891A3 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
02/14/2008WO2007149382A3 Therapeutic compositions and methods useful in treating hepatitis
02/14/2008WO2007149211B1 Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
02/14/2008WO2007148341A3 Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
02/14/2008WO2007146920A3 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
02/14/2008WO2007146224A3 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
02/14/2008WO2007146124A3 Deuterated tadalafil derivatives
02/14/2008WO2007146066A3 Novel piperazines, pharmaceutical compositions and methods of use thereof
02/14/2008WO2007143600A3 Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
02/14/2008WO2007143456A3 Benzimidazol substituted thiophene derivatives with activity on plk
02/14/2008WO2007143131A9 Prednisolone sodium phosphate formulations
02/14/2008WO2007143061A3 Prednisolone salt formulations
02/14/2008WO2007142725A3 Combination of gyrase b inhibitors and protein synthesis inhibitors and uses thereof
02/14/2008WO2007140285A3 Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
02/14/2008WO2007140200A3 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
02/14/2008WO2007139955A8 Triazole compounds that modulate hsp90 activity
02/14/2008WO2007139950A8 Isothiazolinone biocides enhanced by zinc ions
02/14/2008WO2007139950A2 Isothiazolinone biocides enhanced by zinc ions
02/14/2008WO2007138072A3 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
02/14/2008WO2007137149A3 Use of cathepsin k antagonists in bone production
02/14/2008WO2007136302A3 Active substances, pharmaceutical composition and a method for the production and use thereof
02/14/2008WO2007131364A8 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
02/14/2008WO2007130780A3 Benzimidazole modulators of vr1
02/14/2008WO2007127262A3 Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics
02/14/2008WO2007121545A8 S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
02/14/2008WO2007117560A8 Piperidine and morpholine renin inhibitors
02/14/2008WO2007117486A3 Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
02/14/2008WO2007117419A8 Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
02/14/2008WO2007115975A3 USE OF kappa OPIOID RECEPTOR ANTAGONIST-CONTAINING COMPOSITIONS FOR THE TREATMENT OF DISSOCIATIVE DISORDERS
02/14/2008WO2007115381B1 Solid dispersion of poorly soluble drugs in graft copolymers
02/14/2008WO2007114903A3 Treatments using citrulline
02/14/2008WO2007110704A3 Macrolide compositions as therapeutic agent
02/14/2008WO2007106859A3 Phytonutrient compositions from mushrooms or filamentous fungi and methods of use
02/14/2008WO2007103534A3 Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof
02/14/2008WO2007089934A3 Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers
02/14/2008WO2007089616A3 Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
02/14/2008WO2007088473A3 Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
02/14/2008WO2007083017A3 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
02/14/2008WO2007081710A3 Treatment modalities for autoimmune diseases
02/14/2008WO2007081521A3 Salts of potassium atp channel openers and uses thereof
02/14/2008WO2007067567A3 Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or free fatty acid flux
02/14/2008WO2007060208A8 Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same
02/14/2008WO2007042271A3 Nutraceutical composition for the treatment of muscle wasting
02/14/2008WO2007022474B1 HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
02/14/2008WO2007019153A3 Methods for treating hypertension
02/14/2008WO2007018248A9 Pyridone compound
02/14/2008WO2007016435A3 Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
02/14/2008WO2007010283A8 Serine beta-lactamase-like / d-ala carboxypeptidase-like protein
02/14/2008WO2007005633A8 Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
02/14/2008WO2006024627A9 N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
02/14/2008WO2000041670A3 Pharmaceutical forms and methods for penetration continuity
02/14/2008US20080039816 Carbohydrate-Encapsulated Quantum Dots for Bilogical Imaging
02/14/2008US20080039783 System with a reservoir for perfusion management
02/14/2008US20080039779 System with a reservoir for perfusion management
02/14/2008US20080039629 Benzothniazole compositions and their use as ubiquition ligation inhibitors
02/14/2008US20080039622 2,4-pyrimidinediamine compounds and their uses
02/14/2008US20080039611 Cross-linked glycopeptide-cephalosporin antibiotics
02/14/2008US20080039531 Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders
02/14/2008US20080039530 treating a mammal for a vascular permeability disorder by administering a vascular endothelial sphingosine-1-phosphate receptor agonist comprising 2-amino-2-[2-(4-octaphenyl)ethyl]propane-1,3 diol, or 2-amino-2-methyl-4-[4-heptoxy-phenyl]butane-1-ol
02/14/2008US20080039529 Adjunctive Therapy for Depression
02/14/2008US20080039528 Zinc finger ejectors and methods of use thereof
02/14/2008US20080039527 Calixarenes as Inhibitors of Protein Kinase B
02/14/2008US20080039526 Compositions for promoting sleep
02/14/2008US20080039525 Lipid System and Methods of Use
02/14/2008US20080039524 reducing intraocular pressure in glaucoma; Methyl Ester of Methoxypolyethlene Glycol Thiol with DTPA; protect cells, tissues and organs against ionizing radiations, chemotherapy, degenerative diseases, or process that elicit the production of free radicals; remove Ca++, heavy metals
02/14/2008US20080039523 High volume and alternative methods of delivering homeopathic remedies
02/14/2008US20080039522 Composition Containing a Complex Comprising a Metal Ion and a Carboxylate Ligand Having Anti-Inflammatory Activity
02/14/2008US20080039521 Anticancer Effect Enhancer
02/14/2008US20080039520 Anti-first-pass effect compounds
02/14/2008US20080039519 Anti-Demodicosis Agent
02/14/2008US20080039518 Maleiimide anti-tumor phosphatase inhibitors
02/14/2008US20080039517 2-chloro-4-{[(3S)-1-methyl-5-oxo-3-pyrrolidinyl][(2-methylphenyl)methyl]amino}benzonitrile; for treatment of endometreosis, uterine fibroids, dysmenorrhea, menorrhagia, pre-term labor, or infertility
02/14/2008US20080039516 Composition of Solifenacin or Salt Thereof for Use in Solid Formulation
02/14/2008US20080039514 anticholesterol agents; 2-Methyl-2-{3-[3-(4-trifluoromethyl-phenyl)-benzo[d]isoxazol-6-yloxy]-phenoxy}-propionic acid; associated with atherosclerosis and non-insulin dependent diabetes
02/14/2008US20080039513 Marine Compounds with Calcium Channel Blocking Properties for the Treatment of Cognitive or Neurodegenerative Diseases
02/14/2008US20080039512 2-methyl-6-[3-(2-phenyloxazol-4-ylmethoxy)propoxymethyl] benzoic acid
02/14/2008US20080039511 Thiazole Compound and Use Thereof
02/14/2008US20080039510 (1,5-diphenyl-1h-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics
02/14/2008US20080039509 Histone Deacetylase Inhibitors or Novel Benzamine Derivatives with Potent Differentiation and Anti-Proliferation Activity
02/14/2008US20080039508 Treatment Of Tumours
02/14/2008US20080039507 Novel Prostamides For The Treatment Of Glaucoma And Related Diseases
02/14/2008US20080039506 Aminoalcohol Derivatives
02/14/2008US20080039505 5-((((2R)-1-(4-((S)-1-hydroxyhexyl)phenyl)-4-methyl-5-oxopyrrolidin-2-yl)methoxy)methyl)thiophene-2-carboxylic acid; glaucoma or ocular hypertension
02/14/2008US20080039504 ethyl 5-(5-chloro-3-(4-chloro-3-(trifluoromethyl) phenylsulfonamido)pyridin-2-yl)-4-(isoxazol-3-yl)-4H-1,2,4-triazole-3-carboxylate; inflammation; chemokine receptor (CCR 9 or 2) antagonists
02/14/2008US20080039503 Process For The Preparation Of Crystalline Modifications For Use In The Preparation Of Esomeperazole Sodium Salt
02/14/2008US20080039502 e.g. N-[4-(4'-Methoxy-biphenyl-4-yloxymethyl)-5-methyl-furan-2-carbonyl]-benzenesulfonamide; prostaglandin E4 receptor antagonist; analgesic, antiinflammatory agent; migraines and headache
02/14/2008US20080039501 Hydrate forms of amg706
02/14/2008US20080039500 Cerebral Infarction Suppressant
02/14/2008US20080039499 Chemical Compounds
02/14/2008US20080039498 Non-competitive NMDA receptor antagonists
02/14/2008US20080039497 Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases
02/14/2008US20080039496 Method of Modulating Neurite Outgrowth by the use of a Galanin-3 Receptor Antagonist
02/14/2008US20080039495 Diamine Beta2 Adrenergic Receptor Agonists
02/14/2008US20080039494 8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists
02/14/2008US20080039493 Quinuclidine derivatives as M3 antagonists
02/14/2008US20080039492 Quinine products, method of manufacture, and method of use